Authors:  Funmilayo I. Tade, Rebecca A. Sajdak, CNMT, RT(N), FSNMMI-TS, Mehdat Gabriel, Robert H. Wagner, and Bital Savir-Baruch

¹⁸F-fluciclovine is a Food and Drug Administration–approved PET tracer indicated for patients suspected to have recurrent prostate cancer based on a prostate-specific antigen rise after prior therapy. ¹⁸F-fluciclovine PET/CT is performed significantly differently from ¹⁸F-FDG PET/CT and requires special attention to patient preparation, injection technique, and imaging time. This article aims to provide nuclear medicine technologists with the best-practice guidelines for the ¹⁸F-fluciclovine PET/CT protocol.